

Resistenzepidemiologie – Entwicklungen bei gramnegativen Erregern

Sören Gatermann




Nationales Referenzzentrum für gramnegative Krankenhauserreger


RUHR
UNIVERSITÄT
BOCHUM

RUB


Deutliche Zunahme von CRE



Meldezahlen
Enterobacteriales




ARS
K. pneumoniae Meropenem



Abfrage SurvStat und ARS 2023-12-03
ARS: Intensivstationen

Einsendungen 2023





Nationales Referenzzentrum für gramnegative Krankenhauserreger

RUHR
UNIVERSITÄT
BOCHUM

RUB

Einsendungen 2023





Nationales Referenzzentrum für gramnegative Krankenhauserreger

RUHR
UNIVERSITÄT
BOCHUM

RUB

Anstieg der Carbapenemasenachweise




Nationales Referenzzentrum für gramnegative Krankenhauserreger


KUMK
UNIVERSITÄT
BOCHUM

RUB



Enterobacterales: Mehr MBL und Doppelcarbapenemases



OXA-48-like	1255	39%
MBL (NDM/VIM)	1346	42%
KPC	616	19%



P. aeruginosa



Enterobacterales

K. pneumoniae und *E. coli*

	Ceftazidim-Avibactam			Meropenem-Vaborbactam			Cefiderocol		
	S	R	S	R	ATU	S	R	ATU	
OXA-48	99,4	0,6	50,4	49,6	15,2	74,5	25,5	17,4	
OXA-244	99,7	0,3	89,9	10,1	5,3	80,2	19,8	12,4	
NDM-1/-5	0,5	99,5	0,2	99,8	5,6	4,3	95,7	12,1	
VIM-1	0,5	99,5	15,3	84,7	38,3	36,6	63,4	34,4	






Pseudomonas

P. aeruginosa


	Ceftazidim-Avibactam			Meropenem-Vaborbactam		Cefiderocol		
	S	R	ATU	S	R	S	R	ATU
NDM-1		100			100	5,5	94,5	19,5
VIM-2	0,2	99,8		6,7	93,3	91,7	8,3	2,6
Kein Enzym	16,1	83,9	10,5	14,3	85,7	88,2	11,8	5,5




K. pneumoniae mit NDM-4




K. pneumoniae NDM-4



MST Cluster 1



MST Cluster 2



Color grouped by column "ST":


16

25

101

1805

no group assigned



Messages

- Gramnegative mit Carbapenemasen nehmen zu
- Wir werden ein MBL-Land
- Zur Ausbruchserkennung wird die genaue Carbapenemase gebraucht

